ABSTRACT
CRISPR-based transcriptional activation is a powerful tool for functional gene interrogation; however, delivery difficulties have limited its applications in vivo. Here, we created a mouse model expressing all components of the CRISPR-Cas9 guide RNA-directed Synergistic Activation Mediator (SAM) from a single transcript that is capable of activating target genes in a tissue-specific manner. We optimized Lipid Nanoparticles and Adeno-Associated Virus guide RNA delivery approaches to achieve expression modulation of one or more genes in vivo. We utilized the SAM mouse model to generate a hypercholesteremia disease state that we could bidirectionally modulate with various guide RNAs. Additionally, we applied SAM to optimize gene expression in a humanized Transthyretin mouse model to recapitulate human expression levels. These results demonstrate that the SAM gene activation platform can facilitate in vivo research and drug discovery.
Subject(s)
CRISPR-Cas Systems/genetics , Hypercholesterolemia/genetics , Liposomes/pharmacology , Prealbumin/metabolism , Transcriptional Activation/genetics , Animals , Cell Line , Gene Expression/genetics , Gene Expression Regulation/genetics , Genetic Engineering/methods , HEK293 Cells , Humans , Hypercholesterolemia/pathology , Mice , Mice, Inbred C57BL , Mice, Transgenic , Nanoparticles , Prealbumin/genetics , RNA, Guide, Kinetoplastida/genetics , RNA, Guide, Kinetoplastida/metabolismABSTRACT
The filarial nematode Brugia malayi represents a leading cause of disability in the developing world, causing lymphatic filariasis in nearly 40 million people. Currently available drugs are not well-suited to mass drug administration efforts, so new treatments are urgently required. One potential vulnerability is the endosymbiotic bacteria Wolbachia-present in many filariae-which is vital to the worm. Genome scale metabolic networks have been used to study prokaryotes and protists and have proven valuable in identifying therapeutic targets, but have only been applied to multicellular eukaryotic organisms more recently. Here, we present iDC625, the first compartmentalized metabolic model of a parasitic worm. We used this model to show how metabolic pathway usage allows the worm to adapt to different environments, and predict a set of 102 reactions essential to the survival of B. malayi. We validated three of those reactions with drug tests and demonstrated novel antifilarial properties for all three compounds.
Subject(s)
Brugia malayi/drug effects , Drug Evaluation, Preclinical , Filariasis/drug therapy , Filaricides/pharmacology , Symbiosis , Wolbachia/drug effects , Animals , Brugia malayi/microbiology , Metabolic Networks and Pathways/drug effects , Models, Biological , Symbiosis/drug effectsABSTRACT
Numerous challenges have impeded HIV-1 vaccine development. Among these is the lack of a convenient small animal model in which to study antibody elicitation and efficacy. We describe a chimeric Rhabdo-Immunodeficiency virus (RhIV) murine model that recapitulates key features of HIV-1 entry, tropism and antibody sensitivity. RhIVs are based on vesicular stomatitis viruses (VSV), but viral entry is mediated by HIV-1 Env proteins from diverse HIV-1 strains. RhIV infection of transgenic mice expressing human CD4 and CCR5, exclusively on mouse CD4+ cells, at levels mimicking those on human CD4+ T-cells, resulted in acute, resolving viremia and CD4+ T-cell depletion. RhIV infection elicited protective immunity, and antibodies to HIV-1 Env that were primarily non-neutralizing and had modest protective efficacy following passive transfer. The RhIV model enables the convenient in vivo study of HIV-1 Env-receptor interactions, antiviral activity of antibodies and humoral responses against HIV-1 Env, in a genetically manipulatable host.
Subject(s)
Antibodies, Viral/biosynthesis , CD4-Positive T-Lymphocytes/immunology , HIV-1/genetics , Reassortant Viruses/genetics , Vesiculovirus/genetics , env Gene Products, Human Immunodeficiency Virus/genetics , Animals , Antibody Specificity , CD4 Antigens/genetics , CD4 Antigens/immunology , CD4 Lymphocyte Count , CD4-Positive T-Lymphocytes/virology , Disease Models, Animal , Founder Effect , Gene Expression , HIV Infections/genetics , HIV Infections/immunology , HIV Infections/virology , HIV-1/immunology , Humans , Mice , Mice, Transgenic , Reassortant Viruses/immunology , Receptors, CCR5/genetics , Receptors, CCR5/immunology , Vesiculovirus/immunology , Viral Tropism/genetics , Viral Tropism/immunology , Virus Internalization , env Gene Products, Human Immunodeficiency Virus/immunologyABSTRACT
To replicate in a new host, lentiviruses must adapt to exploit required host factors and evade species-specific antiviral proteins. Understanding how host protein variation drives lentivirus adaptation allowed us to expand the host range of HIV-1 to pigtail macaques. We have previously derived a viral swarm (in the blood of infected animals) that can cause AIDS in this new host. To further exploit this reagent, we generated infectious molecular clones (IMCs) from the viral swarm. We identified clones with high replicative capacity in pigtail peripheral blood mononuclear cells (PBMC) in vitro and used in vivo replication to select an individual IMC, named stHIV-A19 (for simian tropic HIV-1 clone A19), which recapitulated the phenotype obtained with the viral swarm. Adaptation of HIV-1 in macaques led to the acquisition of amino acid changes in viral proteins, such as capsid (CA), that are rarely seen in HIV-1-infected humans. Using stHIV-A19, we show that these CA changes confer a partial resistance to the host cell inhibitor Mx2 from pigtail macaques, but that complete resistance is associated with a fitness defect. Adaptation of HIV-1 to a new host will lead to a more accurate animal model and a better understanding of virus-host interactions.
